Skip to main content

PD Pharma Insights

Expert insights into Quality Management Systems (QMS), Quality Risk Management (QRM), and Sterile Validation. Managed by Prashant Devmore (M.Pharm), an Associate Manager with 11+ years of experience at Zydus, Cipla, and Indoco. Specializing in Computer System Validation (CSV), 21 CFR Part 11 compliance, and USFDA/MHRA audit readiness.

Search This Blog

Pages

Jobs
More Posts
About PD Pharma Insights
Sitemap
Privacy Policy
Contact Us
Disclaimer

Posts

The 2026 Guide to Pharmaceutical Validation: How to Save 40% Time Using Digital QA Tools & CSA Frameworks

by Prashant Suresh Devmore March 03, 2026

Digital Transformation

+

Get link
Facebook
X
Pinterest
Email
Other Apps

Prashant Devmore

Prashant Devmore

M. Pharm | 11+ Years QA Expert

Founder of PD Pharma Insights. Leveraging a decade of leadership at Cipla, Indoco, and Zydus to bridge technical excellence and regulatory compliance in Biopharmaceutics.

Connect on LinkedIn Subscribe for Insights

Empowering Pharma Professionals Since 2024

Expertise Areas

AI In Healthcare ›
Aseptic Validation ›
Computer System Validation ›
Drug Reviews ›
Quality Risk Management ›
Quality Management System (QMS) ›

Most Popular Industry Insights

The 2026 Guide to Pharmaceutical Validation: How to Save 40% Time Using Digital QA Tools & CSA Frameworks

Executive Abstract: Validation 4.0 at a Glance The Problem: Traditional Computer System Validation (CSV) has created a "Documentation Debt" where teams spend 80% of their time on paperwork and only 20% on actual testing, leading to 6-month delays in Go-Live timelines. The Solution: The transition to Computer Software Assurance (CSA) —backed by the FDA’s 2022/2026 Guidance and GAMP® 5 (2nd Edition) . This shift prioritizes Critical Thinking over rote documentation, leveraging vendor audits and unscripted testing to ensure patient safety without the "Paper-Pushing" burden. Key Outcomes: 40% Reduction in total validation lifecycle time. 60% Fewer Errors by adopting Digital Logbooks and "Paper-on-Glass" technology. Seamless Audit Readiness through real-time ALCOA+ data integrity dashboards. Bottom Line: If you are a validation lead or QA Lead, moving to Digital QA Tools is no longer a luxury—it is the only way to remain competitive and compliant i...

OOS In Pharma: OOS Investigation, Laboratory Investigation, Detailed Review

OOS In Pharma | OOS | Laboratory Investigation | Detailed Review Author: Mrs. Bhagyashree Prashant Devmore ------------------------------------------------------ Out-of-specification ( OOS) in the Pharma industry is one type of investigational tool used for laboratory investigations. Nowadays, the OOS is the first choice that is being inspected by regulatory inspectors during laboratory audits. More often OOS investigations are required in the pharmaceutical industry to identify the potential contributing factors that are affecting the quality of the product. So, in this post, we will cover the following, 1. What is OOS in pharma? 2. What are the basic concepts of the OOS? 3. How to investigate OOS?

Aseptic manufacturing and terminal sterilization difference - Basics of aseptic processing

Aseptic manufacturing and terminal sterilization difference - Basics of aseptic processing This post is related to pharmaceutical sterile drug manufacturers. So many sterile dosage forms are there and all of them are either terminally sterilized or aseptically manufactured. There is a huge difference between aseptic manufacturing and terminal sterilizatio n . Both these are the sterile process.

Subscribe Us

Prashant Devmore

Associate Manager | QA & Validation
M.Pharm | 11+ Years Experience

Connect on LinkedIn

Ad Code

Responsive Advertisement

Categories

Home
Features
_Multi DropDown
__DropDown 1
__DropDown 2
__DropDown 3
_ShortCodes
_SiteMap
_Error Page
Documentation
_Web Documentation
_Video Documentation
Download This Template

Footer Menu Widget

Home
About
Contact Us

Social Plugin

Powered by Blogger

Prashant Devmore https://pdtechreviews.blogspot.com/